Associated tags: Central nervous system, CB2, Medication, GPCR, CNS, G protein-coupled receptor, Research, Seizure, DSM-IV codes, Biotechnology, Health, Pharmaceutical, Clinical Trials, Pharmaceutical industry, Science, Neurology, Longboard, Other Health
Locations: NEW YORK, EXTON, PA, US, NY, FLORIDA, CALIFORNIA, UNITED STATES, NORTH AMERICA, AUSTRALIA/OCEANIA, AUSTRALIA, CORNERSTONE, AE
Health,
Neurology,
Other Health,
Clinical Trials,
Pharmaceutical,
Biotechnology,
Longboard,
Compensated emancipation,
Medication,
Common stock,
DSM-IV codes,
Employment Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to seven new employees.
Key Points:
- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to seven new employees.
- The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 178,000 shares of its common stock (the “Common Stock”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), which includes an inducement award of options to purchase 30,000 shares of Common Stock granted to Longboard’s Director, Global Field Medical Affairs.
- The stock options were granted on April 30, 2024 (the “Grant Date”) and have an exercise price of $21.30 per share, which is equal to the closing price of the Common Stock on the Grant Date.
- The stock options were granted as an inducement material to the employees entering into employment with Longboard in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the applicable award agreements covering such grants.
Research,
General Health,
Professional Services,
Pharmaceutical,
Infectious Diseases,
Clinical Trials,
Science,
Biotechnology,
Neurology,
FDA,
Finance,
Health,
Other Science,
L.L.C,
Longboard,
Farallon Capital,
Investment,
Private,
Food,
FINANCIAL,
Insurance,
SAD,
AAN,
DSM-IV codes,
Clinical trial,
Medication,
Food and Drug Administration Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results.
Key Points:
- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results.
- In January 2024, Longboard raised $241.5 million in a follow-on public offering.
- Longboard issued and sold 11,500,000 shares of common stock at a public offering price of $21.00 per share.
- In March 2024, Longboard completed a Private Placement with an investment fund affiliated with Farallon Capital Management, L.L.C.
Research,
Clinical Trials,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
General Health,
Other Science,
Science,
Conference,
Medication,
DSM-IV codes Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Dr. Randall Kaye, Longboard’s Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an oral, centrally acting 5-HT2C receptor superagonist, in participants with Developmental and Epileptic Encephalopathies (DEEs) at the AAN Annual Meeting taking place April 13-18, 2024, virtually and in Denver, Colorado.
Key Points:
- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Dr. Randall Kaye, Longboard’s Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an oral, centrally acting 5-HT2C receptor superagonist, in participants with Developmental and Epileptic Encephalopathies (DEEs) at the AAN Annual Meeting taking place April 13-18, 2024, virtually and in Denver, Colorado.
- These data will also be presented at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII), which will take place in Madrid, Spain, May 5-8, 2024.
Biotechnology,
Neurology,
Health,
Pharmaceutical,
Clinical Trials,
Common stock,
Longboard,
Employment,
Compensated emancipation,
Medication,
DSM-IV codes Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to three new employees.
Key Points:
- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to three new employees.
- The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 99,500 shares of its common stock (the “Common Stock”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- The stock options were granted on March 31, 2024 (the “Grant Date”) and have an exercise price of $21.60 per share, which is equal to the closing price of the Common Stock on the last trading day preceding the Grant Date.
- The stock options were granted as an inducement material to the employees entering into employment with Longboard in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the applicable award agreement covering such grant.
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Health,
Clinical Trials,
Other Health,
Medication,
Seizure,
Standard of care,
LGS,
DEE,
DS,
Safety,
SAD,
FDA,
DSM-IV codes,
Pharmaceutical industry Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported full year 2023 financial results.
Key Points:
- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported full year 2023 financial results.
- “I am extremely proud of what our team has accomplished starting with the immense effort that went into the PACIFIC Study in participants with DEEs.
- We appreciate the tremendous support from our existing and new shareholders who play an integral part in the continued success of Longboard.
- Of note, results were on top of current standard of care; participants were typically on 3-4 other anti-seizure medications.
Biotechnology,
Neurology,
Health,
Pharmaceutical,
Clinical Trials,
Compensated emancipation,
Common stock,
Medication,
Longboard,
Employment,
DSM-IV codes Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to four new employees.
Key Points:
- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to four new employees.
- The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 184,000 shares of its common stock (the “Common Stock”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- The stock options were granted on February 29, 2024 (the “Grant Date”) and have an exercise price of $22.18 per share, which is equal to the closing price of the Common Stock on the Grant Date.
- The stock options were granted as an inducement material to the employees entering into employment with Longboard in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the applicable award agreement covering such grant.
Retrieved on:
Tuesday, February 6, 2024
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
Biotechnology,
Neurology,
Health,
Pharmaceutical,
Clinical Trials,
DSM-IV codes,
Common stock,
Longboard,
Employment,
Medication,
Compensated emancipation Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to five new employees.
Key Points:
- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to five new employees.
- The Compensation Committee of the Board of Directors of Longboard approved the grants of non-qualified stock options to purchase an aggregate of 145,475 shares of its common stock (the “Common Stock”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- The stock options were granted on January 31, 2024 (the “Grant Date”) and have an exercise price of $21.24 per share, which is equal to the closing price of the Common Stock on the Grant Date.
- The stock options were granted as an inducement material to the employees entering into employment with Longboard in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the applicable award agreement covering such grant.
Retrieved on:
Thursday, February 1, 2024
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present at two upcoming investor conferences in February.
Key Points:
- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present at two upcoming investor conferences in February.
- Details: Presenting in a fireside chat format on Wednesday, February 7, 2024, at 1:00 PM ET and hosting investor meetings in New York, NY
Details: Presenting in a fireside chat format on Wednesday, February 14, 2024, at 3:20 PM ET and hosting virtual investor meetings
Live webcasts of the presentations will be available on the “ Events & Presentations ” page within the Investors Relations section of Longboard’s website at https://www.longboardpharma.com/ .
- The presentations will be archived on the website for at least 30 days following the events.
Research,
Finance,
Clinical Trials,
Professional Services,
Other Health,
Biotechnology,
Pharmaceutical,
Health,
Science,
Other Science,
Telephone,
DSM-IV codes,
Cantor,
Sale,
Form,
Medication,
Attention,
Security (finance),
Capital market,
Exercise Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its voting common stock, including 1,500,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, at a price to the public of $21.00 per share.
Key Points:
- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its voting common stock, including 1,500,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, at a price to the public of $21.00 per share.
- The gross proceeds to Longboard from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately $241.5 million.
- Cantor and Citigroup acted as joint lead book-running managers for the offering, and Wedbush PacGrow and H.C. Wainwright & Co. acted as lead managers for the offering.
- A final prospectus supplement and accompanying prospectuses relating to the offering were filed with the SEC and are available for free on the SEC’s website located at http://www.sec.gov .
